AstraZeneca’s Calquence approved in the EU for the treatment of most common type of leukaemia in adults
The FINANCIAL — AstraZeneca’s Calquence (acalabrutinib), a next-generation selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in the European Union (EU) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL), the most common type of leukaemia in adults. The approval by the European Commission was based on positive results from two Phase III clinical trials, ELEVATE-TN in patients
